What is Roth Capital’s Estimate for TENX FY2027 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital dropped their FY2027 EPS estimates for Tenax Therapeutics in a report issued on Wednesday, March 5th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings of $1.74 per share for the year, down from their previous estimate of $1.82. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ FY2028 earnings at $2.94 EPS.

Tenax Therapeutics Price Performance

NASDAQ TENX opened at $5.95 on Friday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The business’s 50-day moving average is $6.45 and its 200 day moving average is $5.15.

Institutional Investors Weigh In On Tenax Therapeutics

A number of large investors have recently added to or reduced their stakes in TENX. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the 3rd quarter worth $173,000. Vestal Point Capital LP bought a new position in Tenax Therapeutics in the 3rd quarter worth about $288,000. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics during the third quarter valued at approximately $101,000. Geode Capital Management LLC lifted its position in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Tenax Therapeutics during the fourth quarter valued at approximately $1,026,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.